In vitro time-kill curves of cefepime and cef pirome combined with amikacin, gentamicin or ciprofloxacin against klebsiella pneumoniae producing extended-spectrum beta-lactamase

Chemotherapy

Volumn 43, Issue 4, 1997, Pages 245-253

  Elkhaili H ^a   Kamili, N ^a   Linger, L ^a   Leveque D ^a   Pompei, D ^a   Monteil, H ^a   Jehl, F ^a  

^a Institut de Bacteriologie   (France)

Author keywords

Antibiotic combination; Cefepime; Cefpirome; Extended spectrum lactamase; Klebsiella pneumoniae; Time kill curve

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAMASE; CEFEPIME; CEFPIROME; CIPROFLOXACIN; GENTAMICIN;

ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; TIME;

EID: 0343376093     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000239575     Document Type: Article

References (25)

1. Sanders CC, Sanders WE Jr: Clinical importance of inducible beta-lac-tamases in Gram-negative bacteria. Eur J Clin Microbiol 1987;6:435-437.
2. Mathieu D, Neviere R, Roussel-Del-vallez M, Henrengt F, Chagnon JL, Wattcl F: Traitmcnt des pneumopathies nosocomiales dues à des Klebsiella sécréteurs de bêta-lactamase à spectre étendu par le céfotétan associé à Famikacine. Méd Mal Infect 1993;23:573-576.
3. Horan T, Culver D, Jarvis W: Pathogens causing nosocomial infections. CDC: Antinticrob Newslett 1988;5:65-67.
4. Nikaido H, Wezi L, Rosenberg EY: Outer membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins containing me-thoxyamino substituents. Antimi-crob Agents Chemothcr 1990;34: 337-342.
5. Hiraoka M, Matsuhisa I, Mitsuha-shi S: Hydrolytic rate at low drug concentrations as a limiting factor in resistance to newer cephalosporins. Rev Infect Dis 1988:10:746-751.
6. Fuchs PC, Jones RN, Barry AL, Thomsberry C: Evaluation of the in vitro activity of BMY-2842. a new broad-spectrum cephalosporin. An-timicrob Agents Chemothcr 1985; 27:679-682.
7. Jacob GA, Medeiros AA: More cx-tended-spcctrum ß-lactamases. An-timicrob Agents Chcmother 1991; 35:1697-1704.
8. Philippon A, Labia R, Jacoby G: Ex-tended-spectrum ß-lactamascs. An-timicrob Agents Chemother 1989; 33:1131-1136.
9. Thabaut A, Acar J, Allouch P, Ariel G. Bcrardi-Grassias L. Bcrgognc-Be-rezin E, et al: Fréquence et distribution des bêta-lactamascs chez 1792 souches de Klebsiella pneumoniae isolées en France entre 1985 et 1988. Pathol Biol 1990;38:459-463.
10. Cleeland R. Grunberg E: Laboratory evaluation of new antibiotics in vitro and in experimental animal infections; in Lorian V (ed): Antibiotics in Laboratory Medicine. Baltimore. Williams & Wilkins. 1986. pp 825-876.
11. Bauemfcind A. Schweighart S, Eberlcin E, Jungwirth R: In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepimc, cefpirome. flomoxef, SCE 2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime. latamoxcf and piperacillin). Infection 1991; 19(suppl 5):264-269.
12. Baltch AL, Smith RP, Ritz W: Comparative antimicrobial activity of FK037. cefpirome, ceftazidime and ccfcpime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp. Chemotherapy 1994;40:391-398.
13. Haag R, Lexa P. Werkhâuserl: Artifacts in dilution pharmacokinetic models caused by adherent bacteria. Antimicrob Agents Chemothcr 1986;29:765-768.
14. Sérazin V, Godard T. Couzon B, Ghnassia JC. Allouch PY: Activité bactéricide de trois céphalosporines de 3c génération associées ou non au sulbactam ou à famikacine vis-à-vis d'une souche d' Enterobacter aeroge-nes productrice d'une bêta-lactamase à spectre élargi (abstract). 15e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse, Paris 1995, p 153.
15. Kieft H. Hoepelman AIM, Knupp CA, Van Dijk A, Brangcr JM, Struy-venberg A. Vcrhoef J: Pharmacokinetics of ccfcpime in patients with the sepsis syndrome. J Antimicrob Chemothcr 1993:32(suppl B): 117-122.
16. Okamoto MP. Chin A, Gill MA, Yellin AE, Berne TV, Hcscltine PNR. et al: Analysis of cefep.me tissue penetration into human appendix. Pharmacotherapy 1991;11: 353-358.
17. Nye KJ, Shi G, Andrews JM, Wise R: Pharmacokinetics and tissue penetration of cefepimc. J Antimicrob Chemother 1989:24:23-28.
18. Van der Auwera P. Klastersky J: Serum bactericidal activity and postantibiotic effect in scrum of patients with urinary tract infection receiving high-dosc amikacin. Antimicrob Agents Chemother 1987:31:1061-1068.
19. Drusano GL: Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988;32:289-297.
20. Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA: Lack of pharmacokinetic interaction between cefe-pime and amikacin in humans. Antimicrob Agents Chemother 1992; 36:1382-1386.
21. Malerczyk V. Maass L, Verho M. Hajdu P. Klesel N, Rangoonwala R: Single and multiple dose pharmacokinetics of intravenous cefpirome (HR 810), a novel cephalosporin derivative. Infection 1987; 15:211-214.
22. Nakayama I, Akieda Y, Yamaji E, Nitta Y, Ohishi M, Katagiri K, et al: Single- and multiplc-dosc pharmacokinetics of intravenous cefpirome (HR 810) to healthy volunteers. J Clin Pharmacol 1992;32:256-266.
23. Meyer BH. Muller FO, Luus HG, Drees B, Rothig HJ, Badian M, et al: Safety, tolerance and pharmacokinetics of cefpirome administered intramuscularly to healthy subjects. J Antimicrob Chemother 1992: 29(suppl A):63-70.
24. Elkha'ili H, Leveque D, Peter JD. Salmon J, Salmon Y. Kaltenbach G, et al: Validation du modele dc mi-croporc Yucatan pour les etudes pharmacocinetiques du ceftriaxone, cefepimc, cefpirome et meropene-me. Med Mai Infect 1996:26:599-604.
25. Shah A, Lcttieri J. Kaiser L, Echols R, Heller AH: Comparative pharmacokinetics and safety of ciprofloxacin 400 mg iv thrice daily versus 750 mg po twice daily. J Antimicrob Chemother 1994;33:795-801.